 |
|
|
| |
|
Lawrence Miller, M.D., Chairman
Mediphase Venture Partners
Mediphase Capital Partners Dr. Miller is a Partner and Founder of Mediphase Venture Partners and Mediphase Capital Partners. He has invested in more than 25 private companies in life sciences/health care.
Prior to founding Mediphase Venture Partners, Dr. Miller was Senior Vice President, Hambrecht & Quist Capital Management in Boston from 1997-1999, where he was responsible for evaluating all healthcare private equity investments.
Dr. Miller is trained as a physician and pharmacologist and is currently Adjunct Associate Professor of Pharmacology at Tufts and Instructor in Medicine at Harvard Medical School. |  | 
|
Douglas Cole, M.D.
Flagship Ventures Douglas Cole is a partner at Flagship Ventures, where he focuses on Life Science investments. He currently serves on the Boards of Directors of Ensemble Discovery, Tetraphase, Concert Pharmaceuticals, AVEO Pharmaceuticals, CGI Pharmaceuticals, and Morphotek, and is an Observer on the Board of Directors of Alinea, and Alvine. Prior to Flagship, Douglas held senior management positions at Vertex Pharmaceuticals and Cytotherapeutics. He obtained post-graduate training in medicine at the Johns Hopkins Hospital in Baltimore, MD and in neurology the Massachusetts General Hospital in Boston, MA. | |
|
Eric M. Gordon, Ph.D.
Skyline Ventures Dr. Gordon is a partner at Skyline Ventures and has been a distinguished medicinal chemist, company founder and senior executive since the early 1970s. He was head of medicinal chemistry at Squibb and Bristol Myers Squibb in Princeton, where he worked for 18 years. In 1992, he was Vice President of Research and Director of Chemistry at Affymax in Palo Alto, and in 1996, he became scientific co-founder, President and Chief Scientific Officer of Versicor (later Vicuron Pharmaceuticals, which was acquired by Pfizer in 2005). He is an accepted authority on combinatorial chemistry, medicinal chemistry, and creating drugs through enzyme inhibition.
He received his Ph.D. and M.S. in medicinal chemistry from the University of Wisconsin in Madison and conducted post-doctoral work at Yale University. | | |
Karl D. Handelsman
CMEA Ventures Mr. Handelsman joined CMEA Ventures in February 1999. He has been involved with numerous CMEA investments such as: Ambrx, Ensemble Discovery, Ilypsa, Kalypsys, Maxygen, Phenomix, Rigel, Syrrx, and Xenoport. Prior to joining CMEA, Mr. Handelsman was one of the first employees of Tularik, Inc., a drug discovery company, where his business development role spanned corporate partnering, technology licensing, and operations. He was also one of the first employees of the Whitehead Institute, a premier research organization within MIT; and he worked in business development at Millennium Pharmaceuticals.
Mr. Handelsman holds graduate degrees from both MIT and Harvard Medical School. | |
|
Robert Weisskoff, Ph.D.
Fidelity Biosciences Dr. Weisskoff has worked extensively in both academia and the bioscience industry for the past eighteen years. Prior to joining Fidelity in 2004, he held various senior roles in R&D and Business Development at both pharmaceutical and medical device companies. In his academic career, Dr. Weisskoff was Associate Professor of Radiology at Harvard Medical School, and on the faculty of the Harvard-MIT Health Sciences Technology (HST) Program, and performed research at Massachusetts General Hospital, where he was Associate Director of the MGH-NMR Center. There he worked at the intersection of basic research, medical technology development, and clinical research in a variety of areas. | |
|
|
|
|
|
|
